Self-assembled single-atom nanozyme for enhanced photodynamic therapy treatment of tumor.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31953423.
- Also identified by DOI 10.1038/s41467-019-14199-7 and PMC identifier 6969186.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Hypoxia of solid tumor compromises the therapeutic outcome of photodynamic therapy (PDT) that relies on localized O<sub>2</sub> molecules to produce highly cytotoxic singlet oxygen (<sup>1</sup>O<sub>2</sub>) species. Herein, we present a safe and versatile self-assembled PDT nanoagent, i.e., OxgeMCC-r single-atom enzyme (SAE), consisting of single-atom ruthenium as the active catalytic site anchored in a metal-organic framework Mn<sub>3</sub>[Co(CN)<sub>6</sub>]<sub>2</sub> with encapsulated chlorin e6 (Ce6), which serves as a catalase-like nanozyme for oxygen generation. Coordination-driven self-assembly of organic linkers and metal ions in the presence of a biocompatible polymer generates a nanoscale network that adaptively encapsulates Ce6. The resulted OxgeMCC-r SAE possesses well-defined morphology, uniform size distribution and high loading capacity. When conducting the in situ O<sub>2</sub> generation through the reaction between endogenous H<sub>2</sub>O<sub>2</sub> and single-atom Ru species of OxgeMCC-r SAE, the hypoxia in tumor microenvironment is relieved. Our study demonstrates a promising self-assembled nanozyme with highly efficient single-atom catalytic sites for cancer treatment.
Medical subject headings
- Nanoparticles
- Photochemotherapy
- Porphyrins
- Singlet Oxygen